As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

The number of COVID-19 vaccination doses administered per 100 people in Ireland rose to 221 as of Oct 27 2023. This dataset includes a chart with historical data for Ireland Coronavirus Vaccination Rate.

Please see FAQ for latest information on COVID-19 Data Hub Data Flows https://covid-19.geohive.ie/pages/helpfaqs Field label Field Name Explanation Formula

ExtractDate Extract Date Date the data is Extracted

Latitude Latitude

Longitude Longitude

VaccinationDate Vaccination Date Date the Vaccination occurred

VaccineText Vaccine Date Text

AdditionalDose First Booster Dose The general population receiving their first booster dose of a vaccine

ImmunoDose Immunocompromised Dose Those who are immunocompromised receiving an extra dose as part of their primary course

AdditionalDoseCum First Booster Dose Cumulative

ImmunoDoseCum Immunocompromised Dose Cumulative

EligiblePop Population Over 5

PerBoosterDose % Population Boosted Percent of population over 5 with a first booster dose (First Booster Dose Cumulative/Population Over 5)*100

AdditionalDose2 Second Booster Dose The general population receiving a Second booster dose

ImmunoDose2 Second Immunocompromised Dose Those who are immunocompromised receiving an extra Immunocompromised dose

AdditionalDoseCum2 Second Booster Cumulative

ImmunoDoseCum2 Second Immunocompromised Dose Cumulative

EligiblePop2 Population Over 5

PerBoosterDose2 % Population Second Booster Percent of population over 5 with a second booster dose (Second Booster Dose Cumulative/Population Over 5)*100

IntroductionGuidelines for the management of rheumatoid arthritis (RA) recommend using influenza and pneumococcal vaccinations to mitigate infection risk. The level of adherence to these guidelines is not well known in the UK. The aims of this study were to describe the uptake of influenza and pneumococcal vaccinations in patients with RA in the UK, to compare the characteristics of those vaccinated to those not vaccinated and to compare vaccination rates across regions of the UK.MethodsA retrospective cohort study of adults diagnosed with incident RA and treated with non-biologic immunosuppressive therapy, using data from a large primary care database. For the influenza vaccination, patients were considered unvaccinated on 1st September each year and upon vaccination their status changed to vaccinated. For pneumococcal vaccination, patients were considered vaccinated after their first vaccination until the end of follow-up. Patients were stratified by age 65 at the start of follow-up, given differences in vaccination guidelines for the general population.ResultsOverall (N = 15,724), 80% patients received at least one influenza vaccination, and 50% patients received a pneumococcal vaccination, during follow-up (mean 5.3 years). Of those aged below 65 years (N = 9,969), 73% patients had received at least one influenza vaccination, and 43% patients received at least one pneumococcal vaccination. Of those aged over 65 years (N = 5,755), 91% patients received at least one influenza vaccination, and 61% patients had received at least one pneumococcal vaccination. Those vaccinated were older, had more comorbidity and visited the GP more often. Regional differences in vaccination rates were seen with the highest rates in Northern Ireland, and the lowest rates in London.ConclusionsOne in five patients received no influenza vaccinations and one in two patients received no pneumonia vaccine over five years of follow-up. There remains significant scope to improve uptake of vaccinations in patients with RA.

The statistic display the rate of girls* in Northern Ireland who received the full course of human papillomavirus (HPV) immunization from 2008/09 to 2022/23. In 2022/23, **** percent of girls had received the full course of HPV vaccination, this was an increase from the preceding year. The COVID-19 pandemic meant many schools and educational facilities were closed for a long period of time which negatively impacted the HPV vaccination program in the UK.

Quantifying neutralising capacity of circulating SARS-COV-2 antibodies is critical in evaluating protective humoral immune responses generated post-infection/post-vaccination. Here we describe a novel medium-throughput flow cytometry-based micro-neutralisation test to evaluate Neutralising Antibody (NAb) responses against live SARS-CoV-2 Wild Type and Variants of Concern (VOC) in convalescent/vaccinated populations. Flow Cytometry-Based Micro-Neutralisation Test (Micro-NT) was performed in 96-well plates using clinical isolates WT-B, WT-B.1.177.18 and/or VOCs Beta and Omicron. Plasma samples (All Ireland Infectious Diseases (AIID) Cohort) were serially diluted (8 points, half-log) from 1:20 and pre-incubated with SARS-CoV-2 (1h, 37°C). Virus-plasma mixture were added onto Vero E6 or Vero E6/TMPRSS2 cells for 18h. Percentage infected cells was analysed by automated flow cytometry following trypsinisation, fixation and SARS-CoV-2 Nucleoprotein intracellular staining. Half-maximal Neutralisation Titres (NT50) were determined using non-linear regression. Our assay was compared to Plaque Reduction Neutralisation Test (PRNT) and validated against the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Both Micro-NT and PRNT achieved comparable NT50 values. Further validation showed adequate correlation with PRNT using a panel of secondary standards of clinical convalescent and vaccinated plasma samples. We found the assay to be reproducible through measuring both repeatability and intermediate precision. Screening 190 convalescent samples and 11 COVID-19 naive controls (AIID cohort) we demonstrated that Micro-NT has broad dynamic range differentiating NT50s 1/5000. We could also characterise immune-escape VOC Beta and Omicron BA.5, achieving fold-reductions in neutralising capacity similar to those published. Our flow cytometry-based Micro-NT is a robust and reliable assay to quantify NAb titres, and has been selected as an endpoint in clinical trials.

For May 2021, we also show our seroprevalence estimations when “effectively protected vaccinated people” are subtracted from the compartment removed.